MEDICLIN Full Year 2023 Earnings: €0.23 loss per share (vs €0.20 profit in FY 2022)

MEDICLIN (ETR:MED) Full Year 2023 Results

Key Financial Results

• Revenue: €761.6m (up 6.0% from FY 2022).

• Net loss: €10.8m (down by 214% from €9.44m profit in FY 2022).

• €0.23 loss per share (down from €0.20 profit in FY 2022).

revenue-and-expenses-breakdown

All figures shown in the chart above are for the trailing 12 month (TTM) period

MEDICLIN Earnings Insights

The primary driver behind last 12 months revenue was the Post-Acute segment contributing a total revenue of €458.7m (60% of total revenue). Notably, cost of sales worth €617.5m amounted to 81% of total revenue thereby underscoring the impact on earnings. The largest operating expense was Depreciation & Amortisation (D&A) costs, amounting to €58.1m (37% of total expenses). Explore how MED's revenue and expenses shape its earnings.

Looking ahead, revenue is expected to decline by 1.9% p.a. on average during the next 2 years, while revenues in the Healthcare industry in Germany are expected to grow by 4.4%.

Performance of the German Healthcare industry.

The company's shares are down 1.6% from a week ago.

Balance Sheet Analysis

While earnings are important, another area to consider is the balance sheet. See our latest analysis on MEDICLIN's balance sheet health.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.